Welcome to our dedicated page for Silence Therapeutics news (Ticker: SLN), a resource for investors and traders seeking the latest updates and insights on Silence Therapeutics stock.
Silence Therapeutics plc develops siRNA therapies through its proprietary mRNAi GOLD platform and trades in the U.S. through American Depositary Shares under SLN. Company news commonly covers clinical and preclinical updates for RNA-silencing programs in cardiovascular disease, hematology and rare diseases, along with financial results, research presentations and collaboration activity.
Recurring pipeline coverage centers on divesiran, a wholly owned siRNA candidate targeting TMPRSS6 for polycythemia vera, including SANRECO study updates and its FDA Fast Track and Orphan Drug designations. Updates also address platform-derived programs such as SLN312, AstraZeneca collaboration matters, balance-sheet commentary and board or executive changes.
Silence Therapeutics (Nasdaq: SLN), a clinical-stage siRNA therapeutics company, announced that Chief Medical Officer Curtis Rambaran, MD, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 19, 2026 at 2:00 p.m. ET. A live webcast and archived replay will be available in the Investors section of the company website.
Silence Therapeutics (Nasdaq: SLN) reported Q1 2026 results and program updates on May 7, 2026. Key operational items: SANRECO Phase 2 divesiran topline results remain on-track for August 2026, and Phase 1 abstracts for divesiran and SLN312 (AZD1705) were accepted for EHA and EAS 2026 congresses in June and May. Financial highlights: cash, cash equivalents and short-term investments $70.1M, R&D expenses $9.1M, G&A $7.0M, and net loss $15.0M for Q1 2026. Total shares outstanding: 141,703,840.
Silence Therapeutics (Nasdaq: SLN) reported Q4 and full-year 2025 results and business updates on March 5, 2026. Key highlights: topline Phase 2 SANRECO results for divesiran expected 3Q 2026, AstraZeneca will not advance SLN312 beyond Phase 1 and rights revert, and cash totaled $85.1M at year-end.
Full‑year 2025 collaboration revenue fell to $0.6M from $43.3M in 2024; net loss widened to $88.6M ($0.63/share) with R&D and G&A broadly stable.
Silence Therapeutics (NASDAQ: SLN) announced leadership changes effective December 14, 2025. Craig Tooman, who served as President and CEO and a board member since 2022, agreed by mutual consent to end his employment effective 14 December 2025. Iain Ross, the company chairman, will lead on an interim basis with immediate effect. James Ede Golightly, a former non-executive director, was re-appointed to the board. The company said it is in robust health both financially and operationally, and an additional US-based board appointment is anticipated in due course.
Silence Therapeutics (Nasdaq: SLN) said management will take part in a fireside chat at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 8:00 a.m. ET (1:00 p.m. GMT). The event will be available via a live webcast and an archived replay will be posted afterward in the Investors section of the company website.
Silence Therapeutics (Nasdaq: SLN) reported Q3 2025 results and business updates on November 6, 2025. Key highlights include completion of SANRECO Phase 2 enrollment for divesiran in polycythemia vera (48 phlebotomy-dependent patients) and anticipation of topline results in 3Q 2026. The company reported $102.2 million in cash, cash equivalents and short-term investments as of September 30, 2025, which management expects will fund operations into 2028. Q3 operating figures: R&D $20.5M, G&A $5.8M (down $1.9M YoY), and net loss $21.0M (improved from $35.5M a year earlier).
Silence Therapeutics (Nasdaq: SLN) completed enrollment in the SANRECO Phase 2 study of divesiran, a first-in-class siRNA targeting TMPRSS6 for polycythemia vera (PV).
The global, randomized, double-blind, placebo-controlled study enrolled 48 phlebotomy-dependent PV patients. The primary endpoint is the proportion maintaining hematocrit <45% without phlebotomies between weeks 18 and 36. Secondary endpoints include safety, pharmacokinetics, and quality of life. Topline results are anticipated in 3Q 2026. The Phase 2 design incorporates a 12-week dosing interval informed by Phase 1 data showing durable HCT control with infrequent dosing.
Silence Therapeutics (NASDAQ:SLN), a clinical-stage biotechnology company focused on developing siRNA therapies, has announced its participation in two upcoming investor conferences in September 2025.
Management will present at the Morgan Stanley Global Healthcare Conference on September 9 at 5:35 p.m. ET and the H.C. Wainwright Global Investment Conference on September 10 at 12:00 p.m. ET. Both presentations will be available via webcast through the company's investor relations website.
Silence Therapeutics (NASDAQ:SLN) reported Q2 2025 financial results and clinical progress. The company presented encouraging SANRECO Phase 1 data for divesiran in Polycythemia Vera (PV) at EHA 2025, demonstrating durable hematocrit control and elimination of phlebotomy needs. The Phase 2 SANRECO trial has surpassed 50% enrollment and remains on track for completion by year-end 2025.
Financial highlights include $114.2 million in cash and investments, providing runway into 2028. Q2 2025 saw R&D expenses of $17.6 million (up from $13.8M in Q2 2024) and G&A expenses of $5.1 million (down from $7.0M). Net loss widened to $27.4 million compared to $19.8M in Q2 2024.
The company completed Phase 3 readiness activities for zerlasiran in cardiovascular disease and is pursuing partnership discussions. Silence has paused the Phase 1 study of SLN548 to prioritize promising extra-hepatic cell targeting research.
Summary not available.